SS1(dsFv)-PE38 is also called SS1P for short. It is a new drug which is being tested in mesothelioma patients to see if it can increase life span. This drug is still in its testing phase and has not been approved by the Food and Drug Administration agency.
SS1P is a type of drug which combine a protein with a toxin. It combines with cancer cells and then kills them. The drug is administered intravenously and targets the mesothelin. As the drug is still in the early stages of testing all of its benefits are unknown. The side effects are also unknown however in some trials patients have experienced swelling of their feet and ankles.
As more evidence becomes available from the trials on these drugs we will keep the site updated to reflect their progress.